CVRS - Corindus Vascular Robotics, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
2.9000
+0.0300 (+1.05%)
As of 11:28AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.8700
Open2.9500
Bid2.7500 x 1100
Ask0.0000 x 1400
Day's Range2.8500 - 2.9500
52 Week Range0.7100 - 3.1100
Volume395,975
Avg. Volume1,514,135
Market Cap599.43M
Beta (3Y Monthly)2.02
PE Ratio (TTM)N/A
EPS (TTM)-0.1970
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.40
Trade prices are not sourced from all markets
  • Business Wire28 days ago

    Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today its CorPath® GRX System was successfully used to perform a live complex robotic-assisted percutaneous coronary intervention (PCI) at the EuroPCR 2019 Conference in Paris, France on Wednesday, May 22, 2019. Interventional Cardiologist, PCR Vice-Chairman, and Course Director of EuroPCR, Dr. Jean Fajadet performed the procedure from Clinique Pasteur in Toulouse, France.

  • Business Wirelast month

    Corindus to Showcase CorPath® GRX Robotic System at EuroPCR 2019

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will showcase advanced robotic capabilities of the CorPath GRX System at EuroPCR 2019 in Paris, France from May 21-24, 2019. Corindus will use the annual meeting at EuroPCR 2019 to highlight recent milestones in technology development, including the latest CE marked technIQ™ Smart Procedural Automation, automated movements aimed at improving navigation, lesion crossing, and delivery of therapy.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CVRS.A earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Corindus Vascular Robotics Inc Earnings Call

  • Why Corindus Vascular Robotics Is Soaring Today
    Motley Foollast month

    Why Corindus Vascular Robotics Is Soaring Today

    Shares jump even though its first-quarter results fell short of Wall Street's estimates. What can explain the optimism?

  • Corindus Vascular Robotics (CVRS) Reports Q1 Loss, Tops Revenue Estimates
    Zackslast month

    Corindus Vascular Robotics (CVRS) Reports Q1 Loss, Tops Revenue Estimates

    Corindus Vascular (CVRS) delivered earnings and revenue surprises of 0.00% and 4.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Corindus Vascular: 1Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 5 cents per share. The vascular robotic-assisted systems developer posted revenue of $3 million in the period. In the final minutes of trading ...

  • Business Wirelast month

    Corindus Reports First Quarter 2019 Results

    Eleven purchase orders for CorPath GRX Systems as adoption grows

  • ACCESSWIRElast month

    Corindus Vascular Robotics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2019 / Corindus Vascular Robotics, Inc. (NYSE American: CVRS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 ...

  • Business Wirelast month

    Corindus Equips the World’s First Fully Robotic Catheterization Laboratory

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Chesapeake Regional Healthcare in Chesapeake, VA has equipped both of its catheterization labs at Chesapeake Regional Medical Center with CorPath GRX Vascular Robotic Systems, making it the first hospital in the world to adopt vascular robotic systems in all vascular intervention treatment rooms. The outfitted labs will allow physicians to leverage the latest robotic technology for percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) and provide all patients requiring these procedures at Chesapeake Regional access to the latest technology in cardiovascular disease care.

  • Will Corindus Vascular Robotics (CVRS) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Corindus Vascular Robotics (CVRS) Report Negative Earnings Next Week? What You Should Know

    Corindus Vascular (CVRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire2 months ago

    Corindus to Report First Quarter 2019 Financial Results on May 7, 2019

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, today announced that it will release first quarter 2019 financial and business results on Tuesday, May 7, 2019 after the close of the U.S.

  • Business Wire2 months ago

    Corindus Announces First Robotic-Assisted Interventions in Japan for CorPath GRX Post-Market Study

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that the first clinical robotic-assisted PCI procedures in Japan were completed in partnership with Takafumi Ueno, MD, PhD, Director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital. CorPath GRX received Pharmaceutical and Medical Device Agency (PMDA) approval in 2018 and A1 technical fee reimbursement for Japan in March of this year.

  • Business Wire3 months ago

    Corindus Vascular Robotics Files Required Registration Statement for Holders of Recently Completed $19.8 Million Private Placement

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it filed a registration statement on behalf of investors that participated in its recently completed private placement. As previously disclosed, earlier this quarter, Corindus sold shares of its common stock to a large institutional investor and certain existing stockholders with contractual preemptive rights, including Hudson Executive Capital (“HEC”) and BioStar Ventures, for aggregate gross proceeds of approximately $19.8 million. HEC purchased an amount in excess of their allotment under the preemptive rights.

  • The ‘next big thing’ in tech is hiding among the small caps
    MarketWatch3 months ago

    The ‘next big thing’ in tech is hiding among the small caps

    For those who aren’t afraid of going “risk on” right now, here are some high-flying small-cap tech investments to consider, Jeff Reeves reports.

  • Barrons.com3 months ago

    Activist Legion Partners Wants NN to Change Its Name

    The goal is to reflect its medical businesses. Also, SEC filings on Mersana Therapeutics, Corindus Vascular, Merrimack Pharma, Chaparral Energy, and others.

  • These Hedge Funds Were Right Betting On Corindus Vascular Robotics Inc (CVRS)
    Insider Monkey3 months ago

    These Hedge Funds Were Right Betting On Corindus Vascular Robotics Inc (CVRS)

    It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]

  • Why Corindus Vascular Robotics Shares Are Rising Today
    Motley Fool3 months ago

    Why Corindus Vascular Robotics Shares Are Rising Today

    News that an insider is rapidly adding to his position has the stock heading higher.

  • Corindus Vascular Robotics Inc (CVRS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Corindus Vascular Robotics Inc (CVRS) Q4 2018 Earnings Conference Call Transcript

    CVRS earnings call for the period ending December 31, 2018.

  • Associated Press3 months ago

    Corindus Vascular: 4Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 4 cents per share. The vascular robotic-assisted systems developer posted revenue of $4.7 million in the period. For the year, the company ...

  • Business Wire3 months ago

    Corindus Reports Fourth Quarter and Full Year 2018 Results

    Submitted Neurovascular Indication Marking Important Step toward Addressing Stroke Market; Raised $19.8 Million to Fund Ongoing Innovation

  • Business Wire3 months ago

    Corindus Vascular Robotics Announces Additional Closing of Private Placement

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced the execution of an additional closing of the private placement previously announced on February 26, 2019. In the additional closing, existing investors with preemptive rights purchased an aggregate of 3,512,124 shares of the Company’s common stock on the same terms and at the same price of $1.3796 per share as the initial closing through the exercise of such preemptive rights and the purchase of certain additional shares. The Company intends to use the proceeds for general corporate purposes.

  • Business Wire4 months ago

    Corindus to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, today announced that it will release fourth quarter and full year 2018 financial and business results on Tuesday, March 12, 2019 after the close of the U.S.

  • Business Wire4 months ago

    Corindus to Present at 39th Annual Cowen Health Care Conference on March 13, 2019

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer,

  • Business Wire4 months ago

    Corindus Vascular Robotics Announces Closing of Private Placement for $15 Million

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American:CVRS), a leading developer of precision vascular robotics, today announced the execution of a private placement transaction with a large institutional investor pursuant to which it will sell and issue an aggregate of 10,872,716 shares of its common stock, at a purchase price of $1.3796 per share, resulting in aggregate gross proceeds to the Company of approximately $15 million, which the Company expects to receive during the day. The Company intends to use the proceeds for general corporate purposes. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state and other jurisdiction.